Pancreatic α-cell hyperplasia: Facts and myths

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 748-756

  Yu, Run ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; INCRETIN; LIRAGLUTIDE;

CARCINOGENESIS; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MODEL; GENE MUTATION; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; HYPERGLUCAGONEMIA; LABORATORY DIAGNOSIS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET CELL HYPERPLASIA; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GLUCAGON-SECRETING CELLS; HUMANS; HYPERPLASIA; INCRETINS; MICE; MICE, KNOCKOUT; PANCREATIC DISEASES; RECEPTORS, GLUCAGON;

EID: 84895807360     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2952     Document Type: Review

References (63)

1. Gromada J, Franklin I, Wollheim CB. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28:84-116. (Pubitemid 46220851)
2. Habener JF, Stanojevic V. α-Cells come of age. Trends Endocrinol Metab. 2013;24:153-163.
3. Service FJ. Hypoglycemic disorders. N Engl J Med. 1995;332:1144-1152.
4. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153:1039-1048.
5. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011;13:965-971.
6. Ouyang D, Dhall D, Yu R. Pathologic pancreatic endocrine cell hyperplasia. World J Gastroenterol. 2011;17:137-143.
7. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-2604.
8. Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed [published online June 10, 2013]? BMJ. doi:10.1136/bmj.f3680.
9. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316-3323.
10. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes. 2013;62:2178-2180.
11. Holst JJ. Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies? Diabetologia. 2013;56:1869-1872.
12. Yu R, Nissen NN, Dhall D, Heaney AP. Nesidioblastosis and hyperplasia of α cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas. 2008; 36:428-431. (Pubitemid 351591587)
13. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991; 36:933-942.
14. Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg. 1984; 8:561-574. (Pubitemid 15017558)
15. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30:560-574. (Pubitemid 44265008)
16. Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol. 1998;153:223-231. (Pubitemid 28317525)
17. Périgny M, Hammel P, Corcos O, et al. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol. 2009;33:739-748.
18. Henopp T, Anlauf M, Schmitt A, et al. Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab. 2009;94:213-217.
19. Toda K, Souda S, Sueki H, Momiyama T, Kuratani T, Yamabe K. A case report of asymptomatic malignant microglucagonoma. Jpn J Gastroenterol Surg. 1991;24:3012-3016.
20. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, α cell hyperplasia, and islet cell tumor. Pancreas. 2009;38:941-946.
21. Yu R, Dhall D, Nissen N, Zhou C, Ren SG. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS ONE. 2011; 6:e23397.
22. Yu R, Ren SG, Mirocha J. Glucagon receptor is required for longterm survival: a natural history study of the Mahvash disease in a murine model. Endocrinol Nutr. 2012;59:523-530.
23. Brown K, Kristopaitis T, Yong S, Chejfec G, Pickleman J. Cystic glucagonoma: a rare variant of an uncommon neuroendocrine pancreas tumor. J Gastrointest Surg. 1998;2:533-536. (Pubitemid 128423133)
24. Martignoni ME, Kated H, Stiegler M, et al. Nesidioblastosis with glucagon-reactive islet cell hyperplasia: a case report. Pancreas. 2003;26:402-405. (Pubitemid 36529968)
25. Chen HW, Chen HW, Su DH, Shun CT, Liu KL. Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema. J Formos Med Assoc. 2005;104:363-366.
26. Otto AI, Marschalko M, Zalatnai A, et al. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. J Am Acad Dermatol. 2011;65:458-459.
27. Azemoto N, Kumagi T, Yokota T, et al. An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography. Clin Res Hepatol Gastroenterol. 2012;36:e43-e47.
28. Al-Sarireh B, Haidermota M, Verbeke C, Rees DA, Yu R, Griffiths AP. Glucagon cell adenomatosis without glucagon receptor mutation. Pancreas. 2013;42:360-362.
29. Henopp T, Anlauf M, Biskup S, Klöppel G, Sipos B. Genetic alterations in glucagon cell adenomatosis. In: Proceedings from 9th Annual European Neuroendocrine Tumor Society Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; March 7-9, 2012; Copenhagen, Denmark. Abstract C57.
30. Chen M, Gavrilova O, Zhao WQ, et al. Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs α deficiency. J Clin Invest. 2005;115:3217-3227. (Pubitemid 41567586)
31. Furuta M, Yano H, Zhou A, et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA. 1997;94:6646-6651. (Pubitemid 27281918)
32. Syed AB, Mahal RS, Schumm LP, Dachman AH. Pancreas size and volume on computed tomography in normal adults. Pancreas. 2012; 41:589-595.
33. Tonelli F, Giudici F, Fratini G, Brandi ML. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr Pract. 2011;17(suppl 3):33-40.
34. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990-3011.
35. Yu R, Wawrowsky K, Zhou C. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr. 2011;58:258-266.
36. Yu R, Chen CR, Liu X, Kodra JT. Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones. J Mol Endocrinol. 2012;49:69-78.
37. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun. 2002;290:839-843. (Pubitemid 34687519)
38. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA. 2014;43:143-145.
39. Hayashi Y, Yamamoto M, Mizoguchi H, et al. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet α-cells but not of intestinal L-cells. Mol Endocrinol. 2009;23:1990-1999.
40. Longuet C, Robledo AM, Dean ED, et al. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes. 2013;62: 1196-1205.
41. Lu J, Herrera PL, Carreira C, et al. α-Cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology. 2010;138:1954-1965.
42. Efrat S, Teitelman G, Anwar M, Ruggiero D, Hanahan D. Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic α cells. Neuron. 1988;1:605-613.
43. Lee YC, Asa SL, Drucker DJ. Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem. 1992;267:10705-10708.
44. Herbach N, Nagel L, Zwick T, Hermanns W. Multiple glucagon-producing pancreatic neuroendocrine tumors in a horse (Equus caballus) [published online June 17, 2013]. Vet Pathol. doi:10.1177/0300985813492803.
45. Mu J, Jiang G, Brady E, et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe α cell hypertrophy in diet-induced obese mice. Diabetologia. 2011;54:2381-2391.
46. Yan H, Gu W, Yang J, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther. 2009;329:102-111.
47. Gu W, Yan H, Winters KA, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible α-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331:871-881.
48. Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004;113:1571-1581. (Pubitemid 39071680)
49. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276. (Pubitemid 30395416)
50. Nyborg NC, Mølck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes. 2012; 61:1243-1249.
51. Weinstein LS; National Institute of Diabetes and Digestive and Kidney Diseases. Role of the Gnas gene in metabolic regulation. nidb.nih.gov/search/ searchreport.taf?projectbib=Y&ipid=65265&rpid=. Accessed August 19, 2012.
52. Yang J, MacDougall ML, McDowell MT, et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor(GCGR)knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genomics. 2011;12:281.
53. Vincent M, Guz Y, Rozenberg M, et al. Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased α-cell proliferation, and islet neogenesis. Endocrinology. 2003;144:4061-4069. (Pubitemid 37088761)
54. Lee Y, Berglund ED, Wang MY, et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci USA. 2012;109:14972-14976.
55. Webb GC, Akbar MS, Zhao C, Swift HH, Steiner DF. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes. 2002;51:398-405. (Pubitemid 34764795)
56. Yu R, Nissen N, Dhall D. Exocrine pancreas hyperplasia without dysplasia in glucagon receptor knockout mice. Pancreas. 2013;43:143-145.
57. Bhanot S, Watts LM, Sloop KW, et al. Reduction of hepatic glucagon receptor expression with an optimized antisense oligonucleotide increased active GLP-1 levels in cynomolgus monkeys without pancreatic alpha cell expansion or hyperplasia. In: Proceedings from the American Diabetes Association 66th Scientific Session; June 9-13, 2006; Washington, DC. Abstract 1399-P.
58. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011;60:391-397.
59. Shen DM, Lin S, Parmee ER. A survey of small molecule glucagon receptor antagonists from recent patents (2006-2010). Expert Opin Ther Pat. 2011;21:1211-1240.
60. Thorel F, Damond N, Chera S, et al. Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes. 2011;60:2872-2882.
61. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75:53-63. (Pubitemid 26112227)
62. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24:330-337. (Pubitemid 350135956)
63. Harja E, Lord J, Skyler JS. An analysis of characteristics of subjects examined for incretin efforts on pancreatic pathology. Diabetes Technol Ther. 2013;15(3):609-618.